Cardiac PET


Cardiac PET Myocardial Perfusion Imaging (MPI) is a Medicare approved first line test for non-invasive cardiology evaluation that is projected to grow over 60% in the next 5 years.1

Cardiac PET is rapidly being adopted and it’s not a matter of if cardiac PET is coming, it is a matter of when. It is a powerful, non-invasive imaging tool available now that can assess myocardial blood flow (MBF) of the entire coronary circulation and has been demonstrated to be useful in the assessment of microvascular and triple vessel disease. Microvascular disease is known to be highly prevalent in women, as well as patients with cardiometabolic risk factors.2

2. DiCarli MF 2021: doi:10.2967/jnumed.120.254979
Cardiac Imaging Outpatient Services5 Year National Growth Estimate
Cardiac CT12%
Cardiac MRI17.6%
Myocardial PET64.9%
Electrocardiogram7.9 %
Transthoracic ECHO16.4%
Stress Test4.5%

Advisory Board 2019

Take a virtual tour of an IONETIX facility

We provide health systems, hospitals, cardiology, and radiology/nuclear medicine practice groups the opportunity to utilize the most advanced FDA-approved MPI tracer for their Cardiac PET program.

Cardiac PET – ASNC/SNMMI Position Statement1

According to the American Society of Nuclear Cardiology and Society of Nuclear Medicine and Molecular Imaging joint position statement regarding clinical indications for MPI, Cardiac PET is the first line preferred test for patients with known or suspected coronary artery disease (CAD) and are unable to exercise. There are no clinical scenarios where PET should not be considered a preferred test for these patients.

Cardiac PET MPI is the recommended test for patients who meet appropriate use criteria2 and;

  • Prior stress imaging studies considers equivocal or inconclusive
  • Body habitus that may affect image quality (obesity, large breasts, or implants etc.)
  • High risk patients: diabetes, chronic kidney disease, multi-vessel or left main disease
  • Young patients with known CAD in whom repeat testing will be required over their lifetime
  • Patients in whom myocardial blood flow quantitation is required
1. and%20Quality/ASNCandSNMMIJointPETPositionPaper2016.pdf
2. Schindler, TH et al. J Nuclear Med August 2020, 61 (8) 1221-1265.
Learn about Cardiac PET with N-13 Ammonia
N-13 Ammonia Patient


Compact Cyclotron Technology

The backbone of the IONETIX N-13 Ammonia solution is a superconducting compact cyclotron. Featuring a patent-protected design based on superconducting magnets, the ION-12SC compact cyclotron has a substantially smaller footprint than traditional cyclotrons making installation on or near medical campuses more attainable than ever before. The compact cyclotron ensures a consistent and reliable radiopharmaceutical at the point-of-care and provides you with complete control of patient testing schedules.

Download the Fact Sheet
Compact Cyclotron

Ready to elevate your Cardiac PET imaging program?

The time is now to establish a brand-differentiating service that keeps patients close and drives referrals.

Contact us